GlassScriptPhysician profile
Alice J Reed
NPI 1356355796
$1,374.25
in general payments reported to CMS, 2019-2025
19 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.58 · 2020: $378 · 2021: $463 · 2022: $96.37 · 2023: $74.23 · 2024: $151 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $397.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $665.79 | 2020-2022 | |
| Glaxosmithkline, LLC. | $113.09 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $89.19 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.87 | 2019-2024 | Xifaxan |
| Lilly USA, LLC | $73.90 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Arbor Pharmaceuticals, INC. | $71.72 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $46.53 | 2022-2024 | Nuzyra |
| Astellas Pharma US INC | $30.25 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $29.17 | 2024-2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $28.05 | 2021 | |
| Daiichi Sankyo INC. | $27.45 | 2020 | |
| Eisai INC. | $18.02 | 2025 | |
| Genentech USA, INC. | $16.38 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.93 | 2025 | |
| Amneal Pharmaceuticals LLC | $15.07 | 2025 | Unithroid |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $13.31 | 2024 | Rybelsus, Ozempic |
| Redhill Biopharma INC. | $12.79 | 2020 | |
| Pfizer INC. | $11.59 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.